WO2014054005A3 - PREPARACIÓN NANOSOMAL DEL COMPLEJO FORMADO POR QUERCETINA (U OTRO FLAVONOL, FLAVONA O UN DERIVADO DE LOS MISMOS) Y LA 2-HYDROXIPROPIL- β-CICLODEXTRINA PARA USO INTRAVENOSO EN PATOLOGÍA CEREBRAL - Google Patents

PREPARACIÓN NANOSOMAL DEL COMPLEJO FORMADO POR QUERCETINA (U OTRO FLAVONOL, FLAVONA O UN DERIVADO DE LOS MISMOS) Y LA 2-HYDROXIPROPIL- β-CICLODEXTRINA PARA USO INTRAVENOSO EN PATOLOGÍA CEREBRAL Download PDF

Info

Publication number
WO2014054005A3
WO2014054005A3 PCT/IB2013/059067 IB2013059067W WO2014054005A3 WO 2014054005 A3 WO2014054005 A3 WO 2014054005A3 IB 2013059067 W IB2013059067 W IB 2013059067W WO 2014054005 A3 WO2014054005 A3 WO 2014054005A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
flavonol
flavone
quercetin
cyclodextrin
Prior art date
Application number
PCT/IB2013/059067
Other languages
English (en)
French (fr)
Other versions
WO2014054005A2 (es
Inventor
Federico DAJAS
Antonio Tedesco
Fernanda BLASINA
Lucia VAAMONDE
Marcela DIAZ
Original Assignee
Dajas Federico
Antonio Tedesco
Blasina Fernanda
Vaamonde Lucia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dajas Federico, Antonio Tedesco, Blasina Fernanda, Vaamonde Lucia filed Critical Dajas Federico
Priority to US14/433,734 priority Critical patent/US20160317442A1/en
Publication of WO2014054005A2 publication Critical patent/WO2014054005A2/es
Publication of WO2014054005A3 publication Critical patent/WO2014054005A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Abstract

La invención consiste en la preparación de nanósomas de lecitina colesterol, sin propilenglicol, del complejo formado por quercetina (u otro flavonol o flavona o un derivado de los mismos) y la 2-hydroxipropil-β-ciclodextrina, por un proceso que permite su utilización intravenosa segura y eficaz en el tratamiento de la patología cerebral del adulto y el niño recién nacido. La preparación es segura, estabilizando los parámetros hemodinámicos alterados en la hipoxia severa neonatal en cerdos recién nacidos y es eficaz en proteger la función cerebral en modelos de Enfermedad de Parkinson experimental y en cerdos recién nacidos sometidos a hipoxia.
PCT/IB2013/059067 2012-10-04 2013-10-02 PREPARACIÓN NANOSOMAL DEL COMPLEJO FORMADO POR QUERCETINA (U OTRO FLAVONOL, FLAVONA O UN DERIVADO DE LOS MISMOS) Y LA 2-HYDROXIPROPIL- β-CICLODEXTRINA PARA USO INTRAVENOSO EN PATOLOGÍA CEREBRAL WO2014054005A2 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/433,734 US20160317442A1 (en) 2012-10-04 2013-10-02 Nanosomal preparation of the complex formed by quercetin (or another flavonol, flavone or a derivative thereof) and 2-hydroxypropyl-beta-cyclodextrin for intravenous use in cerebral pathological conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60/258,675 2000-12-27
US25867512P 2012-10-04 2012-10-04

Publications (2)

Publication Number Publication Date
WO2014054005A2 WO2014054005A2 (es) 2014-04-10
WO2014054005A3 true WO2014054005A3 (es) 2014-05-30

Family

ID=50435528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/059067 WO2014054005A2 (es) 2012-10-04 2013-10-02 PREPARACIÓN NANOSOMAL DEL COMPLEJO FORMADO POR QUERCETINA (U OTRO FLAVONOL, FLAVONA O UN DERIVADO DE LOS MISMOS) Y LA 2-HYDROXIPROPIL- β-CICLODEXTRINA PARA USO INTRAVENOSO EN PATOLOGÍA CEREBRAL

Country Status (2)

Country Link
US (1) US20160317442A1 (es)
WO (1) WO2014054005A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2672918C1 (ru) * 2017-10-25 2018-11-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский государственный педагогический университет им. А.И. Герцена" (РГПУ им. А.И. Герцена) Средство, обладающее свойством предупреждать гибель ГАМК-ергических нейронов в условиях острой перинатальной гипоксии
CN112544972A (zh) * 2019-09-26 2021-03-26 泰州医药城国科化物生物医药科技有限公司 一种酸枣仁黄酮磷脂复合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005754A2 (en) * 2005-07-01 2007-01-11 Alza Corporation Liposomal delivery vehicle for hydrophobic drugs
CN101301477A (zh) * 2008-07-04 2008-11-12 山西大学 异槲皮苷包合物及其制备方法
CN102058536A (zh) * 2011-01-14 2011-05-18 四川大学 槲皮素羟丙基β－环糊精包和物脂质体及其制备方法和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005754A2 (en) * 2005-07-01 2007-01-11 Alza Corporation Liposomal delivery vehicle for hydrophobic drugs
CN101301477A (zh) * 2008-07-04 2008-11-12 山西大学 异槲皮苷包合物及其制备方法
CN102058536A (zh) * 2011-01-14 2011-05-18 四川大学 槲皮素羟丙基β－环糊精包和物脂质体及其制备方法和用途

Also Published As

Publication number Publication date
WO2014054005A2 (es) 2014-04-10
US20160317442A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
USD727514S1 (en) Cosmetic skin treatment apparatus
PH12016500846B1 (en) Compositions for preventing or treating allergies in infants from or fed by non secretor mothers by providing fucosylated-oligosaccharides in particular among infants at risk or born by c-section
IL245889B (en) Sulfonamide derivatives as bcl-2-selective apoptosis inducers for the treatment of cancer and immune diseases
EP2911664A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
EP2665479A4 (en) METHODS AND MEDICAMENT PRODUCTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
BR112015016358A2 (pt) composições nutritivas contendo um componente neurológico e usos das mesmas
WO2013061161A3 (en) New combination therapies for treating neurological disorders
NZ612504A (en) Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
PH12016500732A1 (en) Use of a modified sweet whey and a modified sweet whey containing infant formula for promoting the postnatal development of the infant central nervous system and related cognitive functions
WO2014145617A3 (en) Novel uses
BR112013025633A2 (pt) nanopartículas à base de lipídios
EP3088898A4 (en) Method for diagnosis of alzheimer's disease and frontotemporal lobar degeneration, diagnostic agent, therapeutic agent, and screening method for said agents
WO2014124142A3 (en) Nanoencapsulated superoxide dismutase and catalase for treating spinal cord injury
EP2946792A4 (en) THERAPEUTIC AGENT AND THERAPY PROCEDURE WITH 1,25D3 MARRS FOR NEUROLOGICAL ILLNESSES SUCH AS MORBUS ALZHEIMER
WO2014054005A3 (es) PREPARACIÓN NANOSOMAL DEL COMPLEJO FORMADO POR QUERCETINA (U OTRO FLAVONOL, FLAVONA O UN DERIVADO DE LOS MISMOS) Y LA 2-HYDROXIPROPIL- β-CICLODEXTRINA PARA USO INTRAVENOSO EN PATOLOGÍA CEREBRAL
USD721469S1 (en) Pants
EP2678009A4 (en) CYSTAMINE ANALOGS FOR THE TREATMENT OF PARKINSON'S DISEASE
WO2015069108A8 (en) Efficacy of dietary dha-phospholipid for brain dha and dpa accretion in neonates
EP2734221A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE BY ADMINISTRATION OF AN ANGIOGENIC MEDIUM
EP2854539A4 (en) PHOSPHONATE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2012149222A3 (en) Methylated coding and non-coding rna genes as diagnostic and therapeutic tools for human melanoma
Aydın et al. Lengthening of QT interval caused by fluconazole in a newborn
CN302054704S (zh) 防护镜(jspdes37)
TH118830S (th) อุปกรณ์เสริมความปลอดภัยสำหรับอุปกรณ์ล็อค

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13844252

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14433734

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 13844252

Country of ref document: EP

Kind code of ref document: A2